Feasibility and Acceptability of the ABC123 Framework for Advanced Cancer Care


  • Org Study ID: 21-5030.cc
  • Secondary ID: N/A
  • NCT ID: NCT05408507
  • Sponsor: University of Colorado, Denver


Pilot study assessing the feasibility and acceptability of the ABC123 framework, as well as goal concordance between patient and clinician stated goals. Patients >60 years old with recently diagnosed advanced, incurable cancer in for a first consultation at a participating medical oncology clinic. The team will pilot test the ABC123 framework delivery by an advanced practice provider working with a medical oncologist to inform the overall care planning process. This framework will routinely incorporate and implement existing resources from these 3 transdisciplinary tenets (geriatric, oncology, and palliative medicine) into initial care planning in a patient-centered manner. The team will follow patients from initial care planning to 6 months post-intervention and assess additional stakeholder feedback on barriers and facilitators to implementation.


The ABC123 care planning framework is aimed at increasing care alignment delivered to older patients with advanced cancer by combining existing tools that represent the principles of geriatrics, oncology, and palliative care. In this pilot study, our primary goals are to assess the feasibility and acceptability of the ABC123 care planning framework and evaluate the framework's impact on the provision of care that aligns with the goals and values of patients. Participants will participate in a series of visits and follow-ups meant to implement and evaluate the ABC123 care planning framework that will take place over the course of six months. The first two visits will consist of 1) a short physical performance battery (SPPB) and estimation of potential for grade 3 chemotherapy toxicity using the Cancer and Aging Research Group chemotherapy toxicity calculator and 2) guided goals of care discussion with an Advanced Practice Provider based on the findings from visit 1. During 1, 3, and 6-month follow-up sessions, participants will complete a survey consisting of several commonly used questionnaires and an interview about experiences and goals. Care providers and institutional stakeholders will also be interviewed at 1, 2, and 3 years after initial implementation to understand experiences and assess the feasibility if the ABC123 framework.

  • Overall Status
  • Start Date
    February 15, 2022
  • Phase
    Not Applicable
  • Study Type


Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A


  • Advanced Cancer


Inclusion Criteria:
1. Provision to sign and date the consent form

- 2. Age >65 years old, or >60 with at least one deficit on a geriatric screen.

- 3. Stated willingness to comply with all study procedures and be available for the duration of the study

- 4. Diagnosis of a solid-tumor cancer that is not curable with surgery or radiation within the 6 mos. prior to consenting. And that would potentially be treated with systemic cytotoxic chemotherapy. If molecular marker status is pending for a particular tumor, patients may still be approached for enrollment in the study.

- 5. New patient consultation within the UCHealth Denver Metro system or newly diagnosed with recurrent metastatic/incurable disease

- 6. English speaking only for the pilot portion
Exclusion Criteria:
1. Have a diagnosis of a different advanced cancer that has required systemic therapy

- 2. Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements

Gender: All

Minimum Age: 60 Years

Maximum Age: N/A

Healthy Volunteers: No


Name: Elizabeth Kessler

Role: Principal Investigator

Affiliation: University of Colorado, Denver

Overall Contact

Name: Elizabeth Kessler

Phone: 7208480170

Email: elizabeth.kessler@cuanschutz.edu


Facility Status Contact